Evidence map›Paper›PMID 25598820›Full record

ReviewClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2014

Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.

Olivia May Dean, Michael Maes, Melanie Ashton, Lesley Berk, Buranee Kanchanatawan, Atapol Sughondhabirom, Sookjareon Tangwongchai, Chee Ng, Nathan Dowling, Gin S Malhi and 1 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Interventions to improve return to work in depressed people.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Abnormalities in Inflammatory Cytokines Confer Susceptible to Chronic Neuropathic Pain-related Anhedonia in a Rat Model of Spared Nerve Injury.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019
    Article
  14. Review
  15. Review
  16. Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities.Annual review of pharmacology and toxicology · 2018
    Review
  17. Review
  18. Review
  19. Article
  20. Role of Inflammation in Suicide: From Mechanisms to Treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Olivia May DeanInnovations in Mental and Physical Health and Clinical Treatments Strategic Research Centre, Deakin University, School of Medicine, Geelong, Australia. ; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia. ; Department of Psychiatry, University of Melbourne, Parkville, Australia.
Michael MaesDepartment of Psychiatry, Chulalongkorn University, Bangkok, Thailand.
Melanie AshtonInnovations in Mental and Physical Health and Clinical Treatments Strategic Research Centre, Deakin University, School of Medicine, Geelong, Australia.
Lesley BerkDepartment of Psychiatry, Chulalongkorn University, Bangkok, Thailand.
Buranee KanchanatawanCentre for Mental Health and Wellbeing Research, Deakin University, School of Psychology, Burwood, Australia.
Atapol SughondhabiromCentre for Mental Health and Wellbeing Research, Deakin University, School of Psychology, Burwood, Australia.
Sookjareon TangwongchaiCentre for Mental Health and Wellbeing Research, Deakin University, School of Psychology, Burwood, Australia.
Chee NgDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, Richmond, Australia.
Nathan DowlingDepartment of Psychiatry, University of Melbourne, The Melbourne Clinic, Richmond, Australia.
Gin S MalhiDiscipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia. ; Department of Psychiatry, CADE Clinic, St. Leonards, Australia.
MIchael BerkInnovations in Mental and Physical Health and Clinical Treatments Strategic Research Centre, Deakin University, School of Medicine, Geelong, Australia. ; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia. ; Department of Psychiatry, University of Melbourne, Parkville, Australia. ; Orygen Youth Health Research Centre, Parkville, Australia. ; Centre of Youth Mental Health, University of Melbourne, Parkville, Australia.
Chulalongkorn University · THFlorey Institute of Neuroscience and Mental Health · AUMelbourne Clinic · AUOrygen Youth Health · AUUniversity of Melbourne · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While current pharmacotherapies are efficacious, there remain a clear shortfall between symptom remission and functional recovery. With the explosion in our understanding of the biology of these disorders, the time is ripe for the investigation of novel therapies. Recently depression is conceptualized as an immune-inflammatory and nitro-oxidative stress related disorder. Minocycline is a tetracycline antibiotic that has anti-inflammatory, pro-oxidant, glutamatergic, neurotrophic and neuroprotective properties that make it a viable target to explore as a new therapy. This double blind, randomised, placebo controlled adjunctive trial will investigate the benefits of 200 mg/day of minocycline treatment, in addition to any usual treatment, as an adjunctive treatment for moderate-severe major depressive disorder. Sixty adults are being randomised to 12 weeks of treatment (with a 4 week follow-up post-discontinuation). The primary outcome measure for the study is mean change on the Montgomery-Asberg Depression Rating Scale (MADRS), with secondary outcomes including the Social and Occupational Functioning Assessment Scale (SOFAS), Clinical Global Impressions (CGI), Hamilton Rating Scale for Anxiety (HAM-A), Patient Global Impression (PGI), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and Range of Impaired Functioning Tool (LIFE-RIFT). Biomarker analyses will also be conducted at baseline and week 12. The study has the potential to provide new treatment targets, both by showing efficacy with a new class of 'antidepressant' but also through the analysis of biomarkers that may further inform our understanding of the pathophysiology of unipolar depression.

Indexed as

Clinical research protocolDepressionInflammationMinocyclineOxidative stress

Identifiers

PMID25598820
PMCPMC4293162
OpenAlexW2128382881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.